MedTrace Logo

Ranolazine in Diastolic Heart Failure

NCT01163734 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-07-12

No results posted yet for this study

Summary

Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled. Study drug will be given as continuous IV infusion followed by oral treatment for 13 days. LV pressures and hemodynamic data will be measured prior to and after administration of study drug. In addition, Doppler ECHO, cardiopulmonary exercise testing (CPET), and NT-pro-BNP determination will be performed. Adverse events and safety labs will be collected and monitored.

Conditions

  • Diastolic Heart Failure

Interventions

DRUG

Ranolazine

Intravenous treatment followed oral treatment for 13 days.

OTHER

Saline 0.9% and placebo tablet

Intravenous treatment followed by oral treatment for 13 days

Sponsors & Collaborators

  • University Medicine Göttingen, Cardiac Center

    collaborator UNKNOWN

  • Gilead Sciences

    lead INDUSTRY

Principal Investigators

  • Lars S. Maier, MD · University Medicine Göttingen, Cardiac Center

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163734 on ClinicalTrials.gov